Q3 EPS Estimate for Tango Therapeutics Lifted by Analyst

Key Points

• Analysts at Wedbush have raised their Q3 2025 earnings per share estimate for Tango Therapeutics from (0.37) to (0.35), while the full-year consensus estimate remains at (1.19) EPS.
• Guggenheim increased its price target for Tango Therapeutics from $8.00 to $10.00 and maintains a "buy" rating, with an average consensus price target set at $11.00.
• Tango Therapeutics reported a Q2 revenue of $3.18 million, significantly below the analyst estimates of $6.41 million, alongside a negative net margin of 599.11%.

Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) - Analysts at Wedbush upped their Q3 2025 earnings per share estimates for shares of Tango Therapeutics in a research note issued to investors on Tuesday, August 5th. Wedbush analyst R. Driscoll now anticipates that the company will post earnings of ($0.35) per share for the quarter, up from their previous estimate of ($0.37). The consensus estimate for Tango Therapeutics' current full-year earnings is ($1.19) per share. Wedbush also issued estimates for Tango Therapeutics' Q4 2025 earnings at ($0.32) EPS, FY2025 earnings at ($1.38) EPS, Q1 2026 earnings at ($0.32) EPS, Q2 2026 earnings at ($0.33) EPS, Q3 2026 earnings at ($0.34) EPS, Q4 2026 earnings at ($0.35) EPS and FY2026 earnings at ($1.33) EPS.

Several other analysts have also issued reports on the stock. Guggenheim increased their price target on shares of Tango Therapeutics from $8.00 to $10.00 and gave the stock a "buy" rating in a research report on Wednesday. HC Wainwright reiterated a "buy" rating and issued a $13.00 target price on shares of Tango Therapeutics in a research report on Monday, April 14th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $11.00.

Tango Therapeutics Stock Performance

NASDAQ:TNGX opened at $6.50 on Thursday. Tango Therapeutics has a 52 week low of $1.03 and a 52 week high of $12.02. The firm's 50-day simple moving average is $5.29 and its 200 day simple moving average is $3.10. The firm has a market cap of $704.54 million, a price-to-earnings ratio of -4.89 and a beta of 1.64.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported ($0.35) earnings per share for the quarter, meeting the consensus estimate of ($0.35). The company had revenue of $3.18 million for the quarter, compared to analyst estimates of $6.41 million. Tango Therapeutics had a negative net margin of 599.11% and a negative return on equity of 73.34%.

Institutional Investors Weigh In On Tango Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Savant Capital LLC bought a new position in Tango Therapeutics in the second quarter valued at about $61,000. CWM LLC increased its stake in shares of Tango Therapeutics by 182.2% in the second quarter. CWM LLC now owns 4,905 shares of the company's stock valued at $25,000 after buying an additional 3,167 shares during the period. Vanguard Personalized Indexing Management LLC raised its holdings in Tango Therapeutics by 91.6% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 20,369 shares of the company's stock valued at $104,000 after buying an additional 9,737 shares during the last quarter. Acadian Asset Management LLC boosted its position in Tango Therapeutics by 96.6% during the 1st quarter. Acadian Asset Management LLC now owns 973,309 shares of the company's stock worth $1,327,000 after buying an additional 478,203 shares during the period. Finally, Jane Street Group LLC boosted its position in Tango Therapeutics by 270.6% during the 1st quarter. Jane Street Group LLC now owns 352,897 shares of the company's stock worth $483,000 after buying an additional 257,668 shares during the period. Institutional investors own 78.99% of the company's stock.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.